Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazarotene Betasone Cream for chronic eczema
ChiCTR2500102511Phase 4Recruiting
- Sponsor
- Shenzhen University General Hospital
- Start
- May 2025
- Modality
- Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of betamethasone dipropionate + tazarotene in atopic dermatitis (AD) (2 arms), sponsored by Shenzhen University General Hospital. Primary endpoint: Effective rate after 4 weeks. Started May 2025; status: recruiting.
02
Drugs
betamethasone dipropionate + tazarotene
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2500102511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102511.